Trials / Completed
CompletedNCT06362265
A Study to Evaluate Pharmacokinetics of LY3209590 in Pediatric Participants With Type 2 Diabetes Mellitus
A Single Dose Study to Evaluate the Pharmacokinetics of LY3209590 in Pediatric Participants With Type 2 Diabetes Mellitus
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 15 (actual)
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- All
- Age
- 10 Years – 17 Years
- Healthy volunteers
- Not accepted
Summary
The main purpose of this study is to evaluate how much of LY3209590 gets into the blood stream after a single dose and how long it takes the body to remove it in pediatric participants with Type 2 Diabetes Mellitus (T2DM). The study will last for approximately 100 days.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | LY3209590 | Administered SC. |
Timeline
- Start date
- 2024-10-10
- Primary completion
- 2026-01-02
- Completion
- 2026-01-02
- First posted
- 2024-04-12
- Last updated
- 2026-03-24
Locations
10 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06362265. Inclusion in this directory is not an endorsement.